Bioidentical Hormone Clinic

at 10 Harley Street, London, W1G 9PF United Kingdom

Dr Theodora Mantzourani is an experienced GP based in Harley Street, London.


Bioidentical Hormone Clinic
10 Harley Street
London W1G 9PF
United Kingdom
Contact Phone
P: 02074671510
Website

Description

Bioidentical hormone replacement Menopause/Andropause Sexual dysfunction Allergy management Functional Thyroid Disease Chronic skin conditions (acne, eczema etc) Antiageing Medicine Functional Medicine IBS and chronic gastrointestinal problems Nutritional Medicine Medical Diets & Body Sculpting Subclinical problem Diagnostics ("I don't feel very well but my doctors cannot find anything wrong with me") Functional approach to complex chronic disease (Diabetes,Auto-Immune Disease, Cardiovascular Disease, Hypertension, Endocrine Disease, Neurodegenerative Disease, Musculosceletal problems)

Opening time

  • Mondays: 09:00- 21:00
  • Tuesdays: 09:00- 21:00
  • Wednesdays: 09:00- 21:00
  • Thursdays: 09:00- 21:00
  • Fridays: 09:00- 21:00

Company Rating

10 Facebook users were in Bioidentical Hormone Clinic. It's a 64 position in Popularity Rating for companies in Health/Medical/Pharmacy category in London, United Kingdom

6400 FB users likes Bioidentical Hormone Clinic, set it to 6 position in Likes Rating for London, United Kingdom in Health/Medical/Pharmacy category

Effectiveness of Compounded Bioidentical Hormone Replacement Therapy: An Observational Cohort Study Abstract Background: Bioidentical Hormone Replacement Therapy (BHRT) is believed it to be a safer and equally effective alternative to Conventional Hormone Therapy for the relief of menopausal symptoms; however, data are needed to support these claims. The objective of this study is to evaluate the effectiveness of compounded BHRT provided in six community pharmacies. Methods: This was an observational cohort study of women between the ages of 18-89 who received a compounded BHRT product from January 1, 2003 to April 30, 2010 in six community pharmacies. Data included patient demographics, comorbidities, therapeutic outcomes, and hormone therapies. Women self-rated menopausal symptoms as absent, mild, moderate, or severe. Descriptive statistics were used to characterize the patient population, BHRT use, and adverse events. Patient symptom severity was compared at baseline and 3 to 6 months follow-up using the Wilcoxon signed-rank test. Results: Women (n = 296) receiving BHRT at Oakdell Pharmacy had a mean (standard deviation) age of 52 (9) years. The most common BHRT dosage forms utilized were topical (71%) and oral (43%). Compounded BHRT regimens were generally initiated at low doses regardless of route. Women experienced a 25% decrease in emotional lability (p < 0.01), a 25% decrease in irritability (p < 0.01), and a 22% reduction in anxiety (p = 0.01) within 3 to 6 months. These women also experienced a 14% reduction in night sweats (p = 0.09) and a 6% reduction in hot flashes (p = 0.50). Conclusions: This study demonstrates that compounded BHRT improves mood symptoms. Larger studies are needed to examine the impact on vasomotor symptoms, myocardial infarction and breast cancer.